Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for 2024, confirming the accuracy and completeness of the financial information. The company’s board of directors, including executive and independent non-executive members, approved the report during a recent meeting. Investors should note that the report complies with PRC Accounting Standards and Hong Kong’s listing rules, reflecting Hepalink’s commitment to transparency.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.